|
1
|
Yano T, Okamoto T, Fukuyama S and Maehara
Y: Therapeutic strategy for postoperative recurrence in patients
with non-small cell lung cancer. World J Clin Oncol. 5:1048–1054.
2014.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Ohnishi S and Takeda H: Herbal medicines
for the treatment of cancer chemotherapy-induced side effects.
Front Pharmacol. 6(14)2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Inoue T, Takagi H, Owada Y, Watanabe Y,
Yamaura T, Fukuhara M, Muto S, Okabe N, Matsumura Y, Hasegawa T, et
al: The efficacy of the Kampo medicine rikkunshito for
chemotherapy-induced anorexia (RICH trial): Study protocol for a
randomized controlled trial. Trials. 18(485)2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Mori K, Kondo T, Kamiyama Y, Kano Y and
Tominaga K: Preventive effect of Kampo medicine (Hangeshashin-to)
against irinotecan-induced diarrhea in advanced non-small-cell lung
cancer. Cancer Chemother Pharmacol. 51:403–406. 2003.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Ichiki M, Wataya H, Yamada K, Tsuruta N,
Takeoka H, Okayama Y, Sasaki J and Hoshino T: Preventive effect of
kampo medicine (hangeshashin-to, TJ-14) plus minocycline against
afatinib-induced diarrhea and skin rash in patients with non-small
cell lung cancer. OncoTargets and Therapy. 10:5107–5113.
2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Ikemoto T, Shimada M, Iwahashi S, Saito Y,
Kanamoto M, Mori H, Morine Y, Imura S and Utsunomiya T: Changes of
immunological parameters with administration of Japanese Kampo
medicine (Juzen-Taihoto/TJ-48) in patients with advanced pancreatic
cancer. Int J Clin Oncol. 19:81–86. 2014.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Amitani M, Amitani H, Sloan RA, Suzuki H,
Sameshima N, Asakawa A, Nerome Y, Owaki T, Inui A and Hoshino E:
The translational aspect of complementary and alternative medicine
for cancer with particular emphasis on Kampo. Front Pharmacol.
6(150)2015.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Takeno N, Inujima A, Shinohara K, Yamada
M, Shibahara N, Sakurai H, Saiki I and Koizumi K: Immune adjuvant
effect of Juzentaihoto, a Japanese traditional herbal medicine, on
tumor vaccine therapy in a mouse model. Int J Oncol. 47:2115–2122.
2015.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Li QF, Shi SL, Liu QR, Tang J, Song J and
Liang Y: Anticancer effects of ginsenoside Rg1, cinnamic acid, and
tanshinone IIA in osteosarcoma MG-63 cells: Nuclear matrix
downregulation and cytoplasmic trafficking of nucleophosmin. Int J
Biochem Cell Biol. 40:1918–1929. 2008.PubMed/NCBI View Article : Google Scholar
|
|
10
|
He BC, Gao JL, Luo X, Luo J, Shen J, Wang
L, Zhou Q, Wang YT, Luu HH, Haydon RC, et al: Ginsenoside Rg3
inhibits colorectal tumor growth through the down-regulation of
Wnt/β-catenin signaling. Int J Oncol. 38:437–445. 2011.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Li L, Wang Y, Qi B, Yuan D, Dong S, Guo D,
Zhang C and Yu M: Suppression of PMA-induced tumor cell invasion
and migration by ginsenoside Rg1 via the inhibition of
NF-κB-dependent MMP-9 expression. Oncol Rep. 32:1779–1786.
2014.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Kamiyama H, Takano S, Ishikawa E, Tsuboi K
and Matsumura A: Anti-angiogenic and immunomodulatory effect of the
herbal medicine ‘Juzen-taiho-to’ on malignant glioma. Biol Pharm
Bull. 28:2111–2116. 2005.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Matsuda T, Maekawa K, Asano K and
Hisamitsu T: Suppressive effect of Juzen-Taiho-To on lung
metastasis of B16 melanoma cells in vivo. Evid Based Complement
Alternat Med. 2011(743153)2011.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Saiki I: A Kampo medicine
‘Juzen-taiho-to’-prevention of malignant progression and metastasis
of tumor cells and the mechanism of action. Biol Pharm Bull.
23:677–688. 2000.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Onishi Y, Yamaura T, Tauchi K, Sakamoto T,
Tsukada K, Nunome S, Komatsu Y and Saiki I: Expression of the
anti-metastatic effect induced by Juzen-taiho-to is based on the
content of Shimotsu-to constituents. Biol Pharm Bull. 21:761–765.
1998.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Shirakabe A, Hata N, Kobayashi N, Okazaki
H, Matsushita M, Shibata Y, Nishigoori S, Uchiyama S, Asai K and
Shimizu W: The prognostic impact of malnutrition in patients with
severely decompensated acute heart failure, as assessed using the
Prognostic Nutritional Index (PNI) and Controlling Nutritional
Status (CONUT) score. Heart Vessels. 33:134–144. 2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Sawabata N, Asamura H, Goya T, Mori M,
Nakanishi Y, Eguchi K, Koshiishi Y, Okumura M, Miyaoka E and Fujii
Y: Japanese Joint Committee for Lung Cancer Registry: Japanese Lung
Cancer Registry Study: First prospective enrollment of a large
number of surgical and nonsurgical cases in 2002. J Thorac Oncol.
5:1369–1375. 2010.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Hong W, Wu Q, Zhang J and Zhou Y:
Prognostic value of EGFR19-del and 21-L858R mutations in patients
with non-small cell lung cancer. Oncol Lett. 18:3887–3895.
2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Akamatsu H, Katakami N, Okamoto I, kato T,
Kim YH, Imamura F, Shinkai M, Hodge RA, Uchida H and Hida T:
Osimertinib in Japanese patientswith EGFR T790M mutation-positive
advanced non-small-cell lung cancer: AURA3 trial. Cancer Sci.
109:1930–1938. 2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Shukuya T, Mori K, Amann JM, Bertino EM,
Otterson GA, Shields PG, Morita S and Carbone DP: Relationship
between overall survival and response or progression free survival
in advanced non-small cell lung cancer patients treated with
anti-PD-1/PD-L1 antibodies. J Thorac Oncol. 11:1927–1939.
2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Passiglia F, Galvano A, Rizzo S, Incorvaia
L, Listi A, Bazan V and Russo A: Looking for the best
immune-checkpoint inhibitor in pre-treated NSCLC patients: An
indirect comparison between nivolumab, pembrolizumab and
atezolizumab. Int J Cancer. 142:1277–1284. 2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Sakurada T, Kakiuchi S, Tajima S,
Horinouchi Y, Okada N, Nishisako H, Nakamura T, Teraoka K, Kawazoe
K, Yanagawa H, et al: Characteristics of and risk factors for
interstitial lung disease induced by chemotherapy for lung cancer.
Ann Pharmacother. 49:398–404. 2015.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Kalisz KR, Ramaiya NH, Laukamp KR and
Gupta A: Immune checkpoint inhibitor therapy-related pneumonitis:
Pattern and management. Radiographics. 39:1923–1937.
2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Michot JM, Bigenwald C, Champiat S,
Collins M, Carbonnel F, Postel-Vinay S, Berdelou A, Varga A,
Bahleda R, Hollebecque A, et al: Immune-related adverse events with
immune checkpoint blockade: A comprehensive review. Eur J Cancer.
54:139–148. 2016.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Brahmer JR, Lacchetti C, Schneider BJ,
Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner
JM, Ginex P, et al: Management of immune-related adverse events in
patients treated with immune checkpoint inhibitor therapy: American
Society of Clinical Oncology clinical practice guideline. J Clin
Oncol. 36:1714–1768. 2018.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Gandhi L, Rodríguez-Abreu D, Gadgeel S,
Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ,
Powell SF, et al: Pembrolizumab plus chemotherapy in metastatic
non-small-cell lung cancer. N Engl J Med. 378:2078–2092.
2018.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Socinski MA, Jotte RM, Cappuzzo F, Orlandi
F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D,
Thomas CA, Barlesi F, et al: Atezolizumab for first-line treatment
of metastatic nonsquamous NSCLC. N Engl J Med. 378:2288–2301.
2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Mori S, Usami N, Fukumoto K, Mizuno T,
Kuroda H, Sakakura N, Yokoi K and Sakao Y: The significance of the
prognostic nutritional index in patients with completely resected
non-small cell lung cancer. PLoS One. 10(e0136897)2015.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Shimizu K, Okita R, Saisho S, Maeda A,
Nojima Y and Nakata M: Preoperative neutrophil/lymphocyte ratio and
prognostic nutritional index predict survival in patients with
non-small cell lung cancer. World J Surg Oncol.
13(291)2015.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Shoji F, Morodomi Y, Akamine T, Takamori
S, Katsura M, Takada K, Suzuki Y, Fujishita T, Okamoto T and
Maehara Y: Predictive impact for postoperative recurrence using the
preoperative prognostic nutritional index in pathological stage I
non-small cell lung cancer. Lung Cancer. 98:15–21. 2016.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Sheng J, Yang YP, Ma YX, Qin T, Hu ZH,
Hong SD, Zhou T, Huang Y, Zhao HY and Zhang L: Low prognostic
nutritional index correlates with worse survival in patients with
advanced NSCLC following EGFR-TKIs. PLoS One.
11(e0147226)2016.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Okada S, Shimada J, Kato D, Tsunezuka H,
Teramukai S and Inoue M: Clinical significance of prognostic
nutritional index after surgical treatment in lung cancer. Ann
Thorac Surg. 104:296–302. 2017.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Hu Y, Shen J, Liu R, Feng Z, Zhang C, Ling
L and Chen L: Prognostic value of pretreatment prognostic
nutritional index in non-small cell lung cancer: A systematic
review and meta-analysis. Int J Biol Markers. 33:372–378.
2018.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Ramos R, Nadal E, Peiró I, Masuet-Aumatell
C, Macia I, Rivas F, Rosado G, Rodriguez P, Ureña A, Padrones
, et al: Preoperative nutritional status assessment predicts
postoperative outcomes in patients with surgically resected
non-small cell lung cancer. Eur J Surg Oncol. 44:1419–1424.
2018.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Kawai H and Ota H: Low perioperative
prealbumin predicts early recurrence after curative pulmonary
resection for non-small-cell lung cancer. World J Surg.
26:2853–2857. 2012.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Nakagawa T, Toyozaki T, Chiba N, Ueda Y
and Gotoh M: Prognostic value of body mass index and change in body
weight in postoperative outcomes of lung cancer surgery. Interact
CardioVasc Thorac Surg. 23:560–566. 2016.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Kawai H, Saito Y and Suzuki Y: Gender
differences in the correlation between prognosis and postoperative
weight loss in patients with non-small cell lung cancer. Interact
CardioVasc Thorac Surg. 25:272–277. 2017.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Braga M, Gianotti L, Vignali A and Carlo
VD: Preoperative oral arginine and n-3 fatty acid supplementation
improves the imminometabolic host response and outcome after
colorectal resection for cancer. Surgery. 132:805–814.
2002.PubMed/NCBI View Article : Google Scholar
|
